# What are investors saying about ImmunityBio Inc. (IBRX) stock?

November 18, 2026

Rumor.io reads what investors post about ImmunityBio Inc. on X, Reddit, Stocktwits and YouTube and uses AI to summarize it each day. Updated November 13, 2026. Source: https://rumor.io/stocks/nasdaq-ibrx/questions

What people say, Nov 19:

- The potential expansion of ImmunityBio's sepsis trial is a key consideration, with the commenter speculating that starting a new trial would be unnecessary if the current one is progressing well.
- A 50-60% success rate in the trial is considered a key measurement for success, with the commenter emphasizing the importance of a simple and clear outcome.
- The complexity of sepsis as a disease is highlighted, with the commenter noting that a clear and simple read on who benefits from the treatment would be more effective in gaining traction than a large and messy dataset.

ImmunityBio Inc. (IBRX) has 0.24% of all stock attention on November 18, 2026, about level with its 30-day average of 0.23%.

|  | Attention | 30-day average attention |
| --- | --- | --- |
| IBRX | 0.24% | 0.23% |

Attention is the share of the likes, replies and reposts on posts about stocks.

## Is IBRX stock sentiment bullish or bearish?

Sentiment on ImmunityBio Inc. (IBRX) is bullish on November 18, 2026: 85% of engagement on its posts is bullish, up from its 30-day average of 77%. That is above all stocks (56%) and the Healthcare sector (61%).

|  | Bullish | Bearish |
| --- | --- | --- |
| IBRX | 85% | 15% |
| IBRX, 30-day average | 77% | 23% |
| Healthcare sector | 61% | 39% |
| All stocks | 56% | 44% |

The share of the likes, replies and reposts on bullish posts and on bearish posts, of the posts that took a side.

### What is the bull case for IBRX stock?

What the bulls say, Nov 18:

- ImmunityBio's mission to improve health outcomes resonates with the community, demonstrating a focus on social responsibility alongside financial gain.
- The recent price drop has been covered by shorts, creating a buying opportunity for investors, with the potential for significant price appreciation in the near future.
- Anktiva's technology has the potential to revolutionize healthcare by addressing the root cause of sepsis, a costly and debilitating condition, and could lead to a significant increase in the company's value.

Bulls hold 85% of engagement on ImmunityBio Inc. (IBRX) posts on November 18, 2026.

### What is the bear case for IBRX stock?

What the bears say, Nov 18:

- The FDA's lengthy review process for ImmunityBio's Anktiva, which has taken over a year, is a significant concern for the company's stock price.
- The delayed PDUFA date for Anktiva's approval, despite an early decision, suggests that the FDA may not be prioritizing the company's product.
- The overwhelming short interest in ImmunityBio, with 126 million shares shorted, may lead to a significant price drop if the shorts are not covered.

Bears hold 15% of engagement on ImmunityBio Inc. (IBRX) posts on November 18, 2026.

## Which topics are investors discussing about IBRX stock?

We train models to sort every post about ImmunityBio Inc. into topics, then summarize what each group is saying. Each figure is the share of the engagement on IBRX posts that went to that topic.

|  | Share of engagement | 30-day average share |
| --- | --- | --- |
| Technical Analysis: chart patterns and price levels | 2% | 3% |

### What does technical analysis say about IBRX stock?

What people say about IBRX's chart, Nov 13:

- The stock price of ImmunityBio, Inc. ($IBRX) has fallen 50% from its 52-week high, yet is still up 300% from its low, and some investors are optimistic about its future.
- The daily chart for $IBRX shows a persistent downtrend, and some analysts believe that the price will stabilize and start to rise.
- $IBRX has experienced significant declines, with some predicting a rally into year-end and January, while others believe the stock may drop to $4.42 or $5.50 before recovering.

Posts about chart patterns and price levels drew 2% of the engagement on ImmunityBio Inc. (IBRX) posts on November 18, 2026, against a 30-day average of 3%.

## What is the latest news on IBRX stock?

- [IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away](https://finance.yahoo.com/healthcare/articles/ibrx-ceo-reveals-fresh-anktiva-063836089.html) (Yahoo Finance, 1d ago)
- [ImmunityBio at UBS Global Biopharma Conference 2026: broadening ANKTIVA](https://www.investing.com/news/transcripts/immunitybio-at-ubs-global-biopharma-conference-2026-broadening-anktiva-93CH-5029040) (Investing.com, 2d ago)
- [IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio’s London Conferences Next Week](https://finance.yahoo.com/markets/stocks/articles/ibrx-stock-focus-institutional-investor-172827066.html) (Yahoo Finance, 5d ago)
- [ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff?](https://finance.yahoo.com/healthcare/articles/immunitybio-ibrx-declining-4-days-004803291.html) (Yahoo Finance, 6d ago)
- [ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026](https://finance.yahoo.com/healthcare/articles/immunitybio-participate-uk-investor-conferences-023100273.html) (Yahoo Finance, 8d ago)

## Who is talking about IBRX stock?

12% of engagement on ImmunityBio Inc. (IBRX) posts on November 18, 2026 comes from people new to posting about it, about level with a 30-day average of 10%.

|  | Newcomers | Regulars |
| --- | --- | --- |
| IBRX | 12% | 88% |
| IBRX, 30-day average | 10% | 90% |
| All stocks | 43% | 57% |

The share of the likes, replies and reposts on IBRX posts that went to people new to posting about it and to regulars.

### What newcomers say (Nov 18)

- Many newcomers are focused on the potential for $IBRX to gain a pivotal trial and a real FDA conversation, driven by Phase 2 sepsis studies with 28-day mortality as the read.
- The timing of the FDA conversation is uncertain, with some speculating that it could be influenced by the company's ability to address supply issues and the potential for a sBLA.
- The potential for $IBRX to gain a new indication in lung cancer, following a successful bladder cancer indication, is seen as a key driver of the stock's value, with some speculating that the lung indication could be the sleeper in the second line.

### What regulars say (Nov 19)

- The regulars are excited about ImmunityBio's Sepsis treatment and think it could be expanded if the trial is going well, with a successful measurement being a 50-60% improvement.
- There is speculation about the PSS ownership, with a mention of "Queen Harper", which may be related to ImmunityBio's leadership or a key stakeholder.
- The regulars are focused on ImmunityBio's stock price, with one user predicting a price of $6.50 for the next day.

## How does IBRX compare with other Healthcare stocks?

We compare Healthcare stocks by attention, our measure of how much of the conversation each one gets. We add up the likes, replies and reposts on every post about Healthcare stocks on X, Reddit, Stocktwits and YouTube. A stock's attention is its share of that total. Each figure is that share.

ImmunityBio Inc. (IBRX) got the 6th most attention on social media of the Healthcare stocks on November 18, 2026: 2.4% of the attention on Healthcare stocks. The others with the most attention were SLS (33%), CAPR (8%), AKAN (6.3%) and UNH (4.2%).

|  | Share of Healthcare attention |
| --- | --- |
| [IBRX](https://rumor.io/stocks/nasdaq-ibrx) | 2.4% |
| [SLS](https://rumor.io/stocks/nasdaq-sls) | 33% |
| [CAPR](https://rumor.io/stocks/nasdaq-capr) | 8% |
| [AKAN](https://rumor.io/stocks/nasdaq-akan) | 6.3% |
| [UNH](https://rumor.io/stocks/nyse-unh) | 4.2% |

### Which stocks are discussed alongside IBRX?

People who post about ImmunityBio Inc. (IBRX) most often also post about PDSB, CADL, IOVA, BNAI, ONC and SLS.

- [What are investors saying about PDSB stock?](https://rumor.io/stocks/nasdaq-pdsb): Insider buying has been observed, which may be interpreted as a bullish signal.
- [What are investors saying about CADL stock?](https://rumor.io/stocks/nasdaq-cadl): Candel Therapeutics, Inc.'s ($CADL) pancreatic publication in a few weeks is expected to be a near-term catalyst, with the BLA (Biologics License Application) validation being a key milestone.
- [What are investors saying about IOVA stock?](https://rumor.io/stocks/nasdaq-iova): Iovance Biotherapeutics' Amtagvi treatment is gaining traction, with sales booming and oncologists recommending it to patients, citing its effectiveness.
- [What are investors saying about BNAI stock?](https://rumor.io/stocks/nasdaq-bnai): The company disclosed multiple Nasdaq listing rule non-compliances, including deficient periodic reports and internal control failures.
- [What are investors saying about ONC stock?](https://rumor.io/stocks/nasdaq-onc)
- [What are investors saying about SLS stock?](https://rumor.io/stocks/nasdaq-sls): The company's stock price was affected by a news event, with the stock price dropping significantly.

## What is Rumor.io?

Prices move on what people believe. Rumor.io measures what they are saying: it reads public posts about stocks, ETFs and crypto on X, Reddit, Stocktwits and YouTube, and reports what investors are talking about.

- What we read: 1.6 billion public posts about 7,500+ stocks, 6,600+ ETFs and 880+ cryptocurrencies, back to 2009.
- What we throw away: Social media is noisy. Our filters remove spam and bots, posts where the name means something else (Apple the fruit), and tickers that two assets share.

The summaries on this page are written by AI from public posts. The one under the heading is from the posts of November 19, 2026, and each of the others shows its own date. Updated November 13, 2026, the date of the oldest. The figures are counts of the posts and the reactions to them. They show what people are saying, which is not the same as what is true, and they do not predict a price.

Attention is an asset's share of the engagement on posts about all stocks. Engagement is the likes, replies and reposts a post receives. [How each metric is counted](https://rumor.io/docs/metrics). [More about Rumor.io](https://rumor.io).
